The University of Miami Health System is starting a clinical trial to further evaluate the safety and efficacy of an investigational cell therapy for the treatment of chronic motor deficit following an ischemic stroke.
Catch up with an ISCI patient and read about her experience with Stem Cell Therapy! (English and Spanish)
As the heart progresses toward heart failure, it produces high levels of a protein called Osteopontin, which is known to activate pathological remodeling of the heart. Lina Shehadeh, Ph.D., assistant professor of medicine, and a team of investigators decided to see if they could find a way to block Osteopontin signaling to prevent — or possibly even reverse — heart failure.